Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.
Toda Y, Iwatsubo T, Nakamura Y, Matsuda N, Miyata M, Jin M, Chen T, Kuribayashi K, Tian Y, Hughes R, Yamamoto J, Muralidharan KK, Rubel C, Hutchison RM, Budd Haeberlein S. Toda Y, et al. Among authors: muralidharan kk. J Prev Alzheimers Dis. 2024;11(5):1260-1269. doi: 10.14283/jpad.2024.106. J Prev Alzheimers Dis. 2024. PMID: 39350371 Free PMC article. Clinical Trial.
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A. Budd Haeberlein S, et al. Among authors: muralidharan kk. J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30. J Prev Alzheimers Dis. 2022. PMID: 35542991 Clinical Trial.
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.
Mallinckrodt C, Tian Y, Aisen PS, Barkhof F, Cohen S, Dent G, Hansson O, Harrison K, Iwatsubo T, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, von Hehn C, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A, Chen T, Budd Haeberlein S. Mallinckrodt C, et al. Among authors: muralidharan kk. J Prev Alzheimers Dis. 2023;10(2):171-177. doi: 10.14283/jpad.2023.6. J Prev Alzheimers Dis. 2023. PMID: 36946443 Clinical Trial.
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.
Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, Grossman M, Isaacson S, Zesiewicz T, Olsson T, Muralidharan KK, Graham DL, O'Gorman J, Haeberlein SB, Dam T. Boxer AL, et al. Among authors: muralidharan kk. Lancet Neurol. 2019 Jun;18(6):549-558. doi: 10.1016/S1474-4422(19)30139-5. Lancet Neurol. 2019. PMID: 31122495 Clinical Trial.
16 results